ANSTO Publications Online

Welcome to the ANSTO Institutional Repository known as APO.

The APO database has been migrated to version 7.5. The functionality has changed, but the content remains the same.

ANSTO Publications Online is a digital repository for publications authored by ANSTO staff since 2007. The Repository also contains ANSTO Publications, such as Reports and Promotional Material. ANSTO publications prior to 2007 continue to be added progressively as they are in identified in the library. ANSTO authors can be identified under a single point of entry within the database. The citation is as it appears on the item, even with incorrect spelling, which is marked by (sic) or with additional notes in the description field.

If items are only held in hardcopy in the ANSTO Library collection notes are being added to the item to identify the Dewey Call number: as DDC followed by the number.

APO will be integrated with the Research Information System which is currently being implemented at ANSTO. The flow on effect will be permission to publish, which should allow pre-prints and post prints to be added where content is locked behind a paywall. To determine which version can be added to APO authors should check Sherpa Romeo. ANSTO research is increasingly being published in open access due mainly to the Council of Australian University Librarians read and publish agreements, and some direct publisher agreements with our organisation. In addition, open access items are also facilitated through collaboration and open access agreements with overseas authors such as Plan S.

ANSTO authors are encouraged to use a CC-BY licence when publishing open access. Statistics have been returned to the database and are now visible to users to show item usage and where this usage is coming from.

Contact the Repository

 

Communities in ANSTO Publications Online

Select a community to browse its collections.

Now showing 1 - 5 of 5

Recent Submissions

No Thumbnail Available
Item
Applications of a PDP-7
(Australian Institute of Nuclear Science and Engineering, 1970-02-16) Scott. MD; Bird, JR; Kenny. MJ; Allen, BJ
Not available see attached scan.
No Thumbnail Available
Item
Uptake of boronated monoclonal antibodies by melanoma cells visualised by track etch autoradiography and electron energy loss spectroscopy.
(Plenum Press, 1992) Moore, DE; Stretch, JR; Dawes, AL; Cockayne, DJH; Allen, BJ; Constantine, G
The monoclonal antibody (MAb) NKI-C3 (Netherlands Cancer Institute) is a murine IgGl known to react with a formalin resistant antigen expressed by more than 95% of human melanomas. In principle, it can be used in the diagnosis of tissue sections for the presence of melanocytes, and with the appropriate level of boron labelling, this antibody could also be used for NCT of melanoma, provided its specificity is not impaired by the labelling process. The present study involves the use of two imaging techniques: first, α-track etch autoradiography to determine the specifiCity of the MAb after boronation, and second, electron energy loss spectroscopy to obtain information at the subcellular level concerning the localisation of the boron label. © Plenum Press
No Thumbnail Available
Item
Liposomes as carriers of boronated thiouracils for NCT of melanoma
(Plenum Press, 1992) Moore, DE; Chandler, AK; Corderoy-Buck, S; Wilson, JG; Allen, BJ
5-(3-(1,2-decaboronyl)propyl)-6-methyl-thiouracil, DBTU-1, and 5-(1,2-decaboronyl-methyl)-6-methyl-thiouracil, DBTU-2, are boron derivative of thiouracil, which is reported to localize in melanoma as a false precursor in the synthesis of melanin. Biodistribution studies with nude mice bearing melanoma xenografts of both murine and human origin revealed only a slow uptake of boron by the various tumors 48-72 hours after intra peritoneal injection of DBTU-1 dissolved in a small volume of dimethyl-sulfoxide. The relatively slow absorption has been related to the very low aqueous solubility of these compounds. The solubility problem can be overcome by either modifying chemically the molecule, or by the design of an alternative drug delivery system to enhance the solubility. In this report, liposomes are examined as an example of the second approach. © Plenum Press
No Thumbnail Available
Item
Design considerations for the proposed HIFAR thermal and epithermal neutron capture therapy facilities
(Plenum Press, 1992) Storr, GJ; Allen, BJ; Harrington, BV; Davis, LR; Elcombe, MM; Meriaty, H
At the Australian Nuclear Science and Technology Organization (ANSTO) the 100kW reactor Moata has been used successfully for Boron Neutron Capture Therapy (BNCT) of murine melanoma xenografts. Envisaged large animal and human irradiations would require a beam from the High Flux Australian Reactor (HIFAR). Attaining a therapeutic beam for BCNT at HIFAR present a challenge in physical design and engineering, as there is restricted access to core neutrons. major modifications to the HIFAR shielding are precluded as this action would require a long shutdown and a significant and costly safety analysis. The only feasible existing beam tube that may provide a BNCT beam is the 28 cm diameter 10H re-entrant hole, located at the core mid-plane. The 10H end-plate is located approximately 9 cm from two outer core fuel elements, separated from them by D2O. The 10H facility is currently used for neutron diffraction studies, and has a collimator installed which reduces the beam to a 5 cm square hole. A description of the 10H beam hole is contained in a calculational optimization study of an epithermal beam for HIFAR. A major component of the study was a comparison of different filter combinations located at the core end of 10H to maximize therapeutic gain at depth in a one-dimensional phantom model. Dose rates in the phantom were shown to lie close to the lower limit of acceptability for BNCT. © Plenum Press
No Thumbnail Available
Item
Regulating the coordination environment of mesopore‐confined single atoms from metalloprotein‐MOFs for highly efficient biocatalysis
(Wiley, 2022-09-08) Liang, JY; Johannessen, B; Wu, ZB; Webster, RF; Yong, J; Zulkifli, MYB; Harbort, JS; Cheok, YR; Wen, HT; Ao, ZM; Kong, B; Chang, SLY; Scott, J; Liang, K
Single‐atom catalysts (SACs) exhibit unparalleled atomic utilization and catalytic efficiency, yet it is challenging to modulate SACs with highly dispersed single‐atoms, mesopores, and well‐regulated coordination environment simultaneously and ultimately maximize their catalytic efficiency. Here, a generalized strategy to construct highly active ferric‐centered SACs (Fe‐SACs) is developed successfully via a biomineralization strategy that enables the homogeneous encapsulation of metalloproteins within metal–organic frameworks (MOFs) followed by pyrolysis. The results demonstrate that the constructed metalloprotein‐MOF‐templated Fe‐SACs achieve up to 23‐fold and 47‐fold higher activity compared to those using metal ions as the single‐atom source and those with large mesopores induced by Zn evaporation, respectively, as well as up to a 25‐fold and 1900‐fold higher catalytic efficiency compared to natural enzymes and natural‐enzyme‐immobilized MOFs. Furthermore, this strategy can be generalized to a variety of metal‐containing metalloproteins and enzymes. The enhanced catalytic activity of Fe‐SACs benefits from the highly dispersed atoms, mesopores, as well as the regulated coordination environment of single‐atom active sites induced by metalloproteins. Furthermore, the developed Fe‐SACs act as an excellent and effective therapeutic platform for suppressing tumor cell growth. This work advances the development of highly efficient SACs using metalloproteins‐MOFs as a template with diverse biotechnological applications. © 2022 The Authors. Advanced Materials published by Wiley-VCH GmbH. Open Access CC-BY-NC-ND.